Eli Lilly's oral weight loss pill, orforglipron Eli Lilly competitor Novo Nordisk kicked off the weight-loss drug craze when it started selling Ozempic ... because it works best when patients ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

The introduction of DeepSeek, a Chinese artificial intelligence (AI) startup, triggered a broad market sell-off on ... unrelenting demand. Eli Lilly (NYSE: LLY) sells many products across ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...